Cisplatin and Carboplatin in Testis and Ovarian Cancer: Pro Cisplatin
The availability of the analogs cisplatin and carboplatin has sparked considerable controversy as to the relative merits of the two agents. A number of randomized clinical trials have been done that address this issue. As expected, most of these trials have been done in the tumor types that are the most responsive to these agents, ovarian and testis cancer.
KeywordsOvarian Cancer Germ Cell Tumor Advanced Ovarian Cancer Southwest Oncology Group Combination Chemotherapy Regimen
Unable to display preview. Download preview PDF.
- Alberts, D. S., Green, S., et al. (1992). Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706.PubMedGoogle Scholar
- Childs, W. J., Nicholls. E. J., et al. (1992). The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol 3:29.Google Scholar
- Conti, P. F., Bruzzone, M., et al. (1991). Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III–IV ovarian carcinoma. J Clin Oncol 9:658.Google Scholar
- Horwich, A. and Sleijfer, D. (1994). Carboplatin-based chemotherapy in good prognosis metastatic non-seminoma of the testis: an interim report of an MRC/EORTC randomised trial. Proc. Leeds Germ Cell Tumour Conference (abstract).Google Scholar
- McGuire, W. P., Hoskins, W. J., et al. (1993). A phase III trial comparing cisplatin/Cytoxan and cisplatin/Taxol in advanced ovarian cancer. Proc Amer Soc Clin Oncol 12: 255 (abstract).Google Scholar